Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position

Bluebird Bio Inc BLUE has agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million.
Bluebird was granted two PRVs upon the FDA approvals of Zynteglo (betibeglogene autotemcel) for beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and Skysona (elivaldogene autotemcel) for early, active cerebral adrenoleukodystrophy.
"As momentum builds across our business, this non-dilutive capital further bolsters the ongoing launches of our two recently approved gene therapies and the execution of near-term, value-creating milestones, including the planned submission and subsequent FDA review of our biologics licensing application for lovo-cel for sickle cell disease," said Andrew Obenshain, CEO, Bluebird bio.
Bluebird continues exploring additional financing opportunities, including monetizing its second PRV, and anticipates providing full 2023 guidance early next year.
Earlier today, Argenx SE ARGX agreed to acquire an FDA Priority Review Voucher for $102 million.
A PRV entitles the holder to FDA priority review of a single Biologics License Application (BLA), which reduces the target review period and may lead to an expedited approval.
Also Read: Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review.
Price Action: BLUE shares are up 1.52% at $7.77 on the last check Wednesday.